The other 10% of EGFR mutations in NSCLC comprise rare mutations such as EGFR ex20ins, G719X, L861Q, and S768I/V, which confer inferior responses to EGFR TKI treatment.2 This evidence concerns the gene EGFR and non-small cell lung carcinoma.